UBS raised the price target for the Ionis Pharmaceuticals Inc. (NASDAQ:IONS) stock from “a Sell” to “a Neutral”. The rating was released on May 07, 2021. We previously noted in another research note published on March 01, 2021 by Barclays that upgraded the stock from an Underweight to an Equal weight with a price target of $52 for IONS stock. The research report from UBS has initiated the stock to Sell, with a price target set at $34. In their research brief published September 14, 2020, JP Morgan analysts resumed the Ionis Pharmaceuticals Inc. stock to Neutral with a price target of $63.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.64 during the last quarter as opposed to a consensus estimate of -$0.52, which indicates the company missed its estimate by -$0.12, which implies that the company surprised the market by -23.10%. It appears that the average earnings per share estimate for the current quarter (ending in Jun 2021) is -$0.56. This is an average of 16 analysts’ earnings, where the high earnings per share estimate is -$0.31 and the low earnings per share estimate is -$0.73. According to 14 analyst estimates, an average revenue estimate of $133.69M is projected for the current quarter with a high revenue estimate of $166M and a low estimate of $108.5M.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Ionis Pharmaceuticals Inc. (NASDAQ:IONS) raised 3.74% to close Thursday’s market session at $36.85, higher as compared to yesterday’s close. The stock price fluctuated between $34.63 and $36.99 throughout the trading session with the volume trading being 9311640 shares, which represented a significant variation when compared to the three months average volume of 1.67 million shares. The firm’s stock price fluctuated 0.79% within the last five trades and -15.40% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -26.36% in the last 6 months and -29.68% was subtracted to its value over the previous 3 months. IONS stock is trading at a margin of -2.93%, -12.01% and -26.60% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, IONS deals in the Healthcare domain. The stock is trading -42.75 percent below its 52-week high and 5.74 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -40.49. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Ionis Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at -28.70 percent and the profit margin is -69.70 percent, and the company has reported a gross margin of 98.30 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $5.24 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 7.41 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 7.63, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.20 percent of Ionis Pharmaceuticals Inc. shares are owned by insiders, and 88.50 percent are held by financial institutions. Monia Brett P, the Chief Executive Officer at Ionis Pharmaceuticals Inc. (IONS) has sold 236 shares of firm on Mar 01 at a price of $54.27 against the total amount of $12809.0. In another inside trade, CROOKE STANLEY T, Exec Chairman of the Board of Ionis Pharmaceuticals Inc. (NASDAQ:IONS) sold 28,333 shares of the firm on Jan 26 for a total worth of $1.81 million at a price of $63.74. An inside trade which took place on Jan 25, EVP & General Counsel of Ionis Pharmaceuticals Inc. O’NEIL PATRICK R. sold 5,324 shares of firm against total price of $0.34 million at the cost of $63.50 per share.